Close
Help





JOURNAL

Clinical Medicine Reviews in Therapeutics

Clinical and Economic Consequences of the Treatment of Postoperative Ileus with Alvimopan

Submit a Paper


Clinical Medicine Reviews in Therapeutics 2011:3 299-309

Review

Published on 14 Jul 2011

DOI: 10.4137/CMRT.S5095


Further metadata provided in PDF

Download Article PDF


Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics

Abstract

Postoperative ileus (POI) increases morbidity and prolongs hospital stay after bowel resection. Alvimopan is a µ-antagonist designed to counteract gastrointestinal side effects of opiates without impairing analgesia due to its inability to pass the blood brain barrier. Because of its association with myocardial events in a long term study where it was applied to treat opiate-induced constipation, approval by the FDA in 2008 for POI is restricted to short term inpatient use. This review gives an overview about pharmacology, efficacy and economic aspects of alvimopan for the treatment of POI. Alvimopan consistently accelerated gastrointestinal recovery in all moderately well designed trials represented by decreasing the time to first bowel movement and tolerance of solid food after surgery. There is limited evidence about its economic impact by shortening the length of hospital stay. Its role in upcoming multimodal perioperative “fast track” programs cannot be defined from currently available data.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)





Quick Links


New article and journal news notification services